NCT07029451 To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
| NCT ID | NCT07029451 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ferring Pharmaceuticals |
| Condition | Infertility |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2025-08-05 |
| Primary Completion | 2028-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2025-08-05 with a primary completion date of 2028-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-centre prospective non-interventional trial to assess the pattern of use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice. There will be approximately 2500 patients initiated with REKOVELLE® treatment and enrolled in 30-50 sites in China. The total duration of the study will be approximately 35 months.
Eligibility Criteria
Inclusion Criteria: * Women who meet all the following criteria are eligible for participation: * At least 20 years of age (including the 20th birthday) when signing informed consent * Prescribed REKOVELLE for the first time in controlled ovarian stimulation for in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles * Willing and able to provide written informed consent Exclusion Criteria: * Women who meet any of the following criteria are not eligible for participation: * Previously undergone more than 1 controlled ovarian stimulation cycles for IVF or ICSI * Currently participating in an interventional clinical study for which treatment with medication is mandated * Currently undergoing ovarian stimulation for fertility preservation or oocytes donation * Contraindications for the use of REKOVELLE
Contact & Investigator
Global Clinical Compliance
STUDY DIRECTOR
Ferring Pharmaceuticals
Frequently Asked Questions
Who can join the NCT07029451 clinical trial?
This trial is open to female participants only, aged 20 Years or older, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07029451 currently recruiting?
Yes, NCT07029451 is actively recruiting participants. Contact the research team at Disclosure@ferring.com for enrollment information.
Where is the NCT07029451 trial being conducted?
This trial is being conducted at Hefei, China, Ma’anshan, China, Beijing, China, Chaoyang, China and 11 additional locations.
Who is sponsoring the NCT07029451 clinical trial?
NCT07029451 is sponsored by Ferring Pharmaceuticals. The principal investigator is Global Clinical Compliance at Ferring Pharmaceuticals. The trial plans to enroll 2,500 participants.